Intensity Therapeutics Raises $6.6 Million in July 2025 Through At-The-Market Stock Sales
Intensity Therapeutics, Inc. bolstered its financial position by securing $6.6 million through at-the-market stock sales, enabling further advancement of its innovative cancer therapy clinical trials.
Intensity Therapeutics, Inc. (Nasdaq: INTS), a biotechnology firm at the forefront of developing intratumoral cancer therapies, reported a significant financial milestone in July 2025. The company successfully raised $6.6 million in gross proceeds through the sale of 19,868,658 shares of its common stock via an At-the-Market (ATM) offering. This strategic move not only strengthens Intensity Therapeutics' balance sheet but also supports the continuation of its clinical trials into the latter half of 2026.
Lewis H. Bender, President and CEO of Intensity Therapeutics, highlighted the advantages of the ATM sales, noting the favorable pricing and lower capital-raising costs compared to previous offerings. The average share price of $0.3323 represented a more than 10% increase over the company's June 2025 public offering, underscoring the market's positive reception to Intensity's innovative approach to cancer treatment.
Intensity Therapeutics' lead product candidate, INT230-6, exemplifies the company's pioneering work in cancer therapy. Designed for direct intratumoral injection, INT230-6 leverages the company's proprietary DfuseRx℠ technology to deliver potent anti-cancer agents directly to tumors, promoting local disease control and stimulating an immune response against cancer cells. This method offers a promising alternative to traditional chemotherapy, with the potential to transform the treatment landscape for various cancers.
The company's clinical endeavors include a Phase 3 trial in soft tissue sarcoma and a Phase 2 study in triple-negative breast cancer, in collaboration with the Swiss Cancer Group. These trials aim to evaluate the efficacy of INT230-6 in improving patient outcomes, with a focus on overall survival and pathological complete response rates. For more information on Intensity Therapeutics and its groundbreaking research, visit https://www.intensitytherapeutics.com.
This financial achievement and the ongoing clinical trials underscore Intensity Therapeutics' commitment to advancing cancer treatment options. The successful ATM sales not only reflect investor confidence in the company's innovative therapies but also provide the necessary resources to further its mission of turning deadly cancers into manageable conditions.